The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

May 12, 2025

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

May 08, 2025

Nerea Lopetegui-Lia, MD, elaborates on several highly anticipated studies evaluating ADCs that could shape the future TNBC treatment paradigm.

April 21, 2025

Nerea Lopetegui-Lia, MD, discusses fertility preservation options for patients with TNBC and considerations for managing treatment-related toxicities.

April 11, 2025

Nerea Lopetegui-Lia, MD, discusses treatment options for patients with chemotherapy-pretreated early-stage high-risk TNBC with residual disease at surgery.

March 23, 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

March 20, 2025

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

November 04, 2024

BXQ-350 was well tolerated and generated clinical activity in patients with advanced solid tumors.

October 30, 2024

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

October 30, 2024

Casey M. Cosgrove, MD, discusses treatment with the ADC T-DXd in patients with ovarian cancer.

October 29, 2024

Casey M. Cosgrove, MD, discusses the evolution of treatment with antibody-drug conjugates for patients with ovarian cancer.

July 17, 2024

Dr. Hannah Choe discusses a clinical scenario of a patient with GVHD who has progressed after multiple lines of treatment. She explores how the availability of CSF-1R inhibitors could fit into the evolving treatment landscape for managing this difficult-to-treat patient population. Dr. Choe provides her perspectives on the potential role and clinical implications of targeting this pathway as an emerging therapeutic approach for GVHD.

July 17, 2024

Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.

July 08, 2024

In this video, Dr. Hannah Choe provides an overview of the background of graft-versus-host disease (GVHD), discusses currently approved treatments and their limitations, and the significant unmet treatment needs in GVHD.

June 27, 2024

David M. O’Malley, MD, and Chandler H. Park, MD, FACP, discuss updates in gynecologic oncology at the 2024 ASCO Annual Meeting.

June 25, 2024

Linvoseltamab demonstrated durable efficacy with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

May 16, 2024

Samilia Obeng-Gyasi, MD, MPH, discusses a retrospective study on neighborhood opportunity and all-cause mortality in patients with breast cancer.

May 15, 2024

Samilia Obeng-Gyasi, MD, MPH, highlights a study on the association between neighborhood opportunity with all-cause mortality in patients with breast cancer.

May 08, 2024

Laura J Chambers, DO, discusses currently approved PARP inhibitors that are considered for use in ovarian cancer.

May 08, 2024

Casey M. Cosgrove, MD, discusses the FDA approval of mirvetuximab soravtansine for adult patients with Frα+, platinum-resistant ovarian cancer.

April 25, 2024

Raj Singh, MD, discusses unmet medical needs in the treatment of patients with lung cancer.